Is Thymosin Alpha-1 safe?

Thymosin Alpha-1 has one of the strongest safety profiles of any research peptide, supported by decades of clinical use in over 35 countries. Side effects are predominantly mild injection-site reactions. No significant organ toxicity has been identified. Caution is warranted in autoimmune conditions due to its immune-enhancing mechanism.

Is Thymosin Alpha-1 FDA-approved?

No. It is not FDA-approved in the United States, despite being approved in over 35 countries as Zadaxin. The FDA approval pathway was not completed. This reflects regulatory process, not a safety or efficacy rejection.

Why is it approved in other countries but not the US?

Thymosin Alpha-1 demonstrated sufficient efficacy for approval in many jurisdictions but did not complete the specific trial program required by the FDA. Different regulatory agencies have different evidentiary standards and approval pathways. The FDA requires specific US-based or US-acceptable trial data that was not submitted.

Does Thymosin Alpha-1 work for healthy people?

The clinical evidence supports immune modulation in immunocompromised populations, including hepatitis patients, cancer patients, and elderly vaccine recipients. Whether it provides meaningful immune benefit to healthy, immunocompetent adults is not established by clinical data. The leap from treating immune deficiency to enhancing normal immune function is not supported.

What is the current regulatory status?

Thymosin Alpha-1 was placed on the FDA's Category 2 restricted list in September 2023, removed in September 2024, and is currently under PCAC (Pharmacy Compounding Advisory Committee) review. Its US compounding status is uncertain pending the PCAC outcome.

What does the research show about: Approved in 35+ countries as Zadaxin, one of the most widely approved immune-mod?

Approved in 35+ countries as Zadaxin, one of the most widely approved immune-modulating peptides globally, yet not FDA-approved in the US. This unusual regulatory split exists because Thymosin Alpha-1 demonstrated sufficient efficacy for approval in many jurisdictions but did not complete the specific trial program required by the FDA

Have any randomized controlled human trials been completed?

Strongest clinical evidence is as an adjunctive therapy for chronic hepatitis B, with multiple controlled trials showing improved viral clearance when combined with interferon. Hepatitis B adjunctive therapy is the most evidence-supported use case, though combination therapy makes it difficult to isolate Thymosin Alpha-1's independent contribution

What mechanism of action has been identified?

Immune modulation mechanism acts primarily through dendritic cell maturation and T-cell differentiation, enhancing rather than suppressing immune function. This immunostimulatory (not immunosuppressive) profile distinguishes Thymosin Alpha-1 from many conventional immune-modulating drugs and positions it as an adjunctive rather than primary therapy

What does the research show about: Cancer immunotherapy interest is growing but evidence is limited to small studie?

Cancer immunotherapy interest is growing but evidence is limited to small studies and case series, with no large oncology RCTs completed. The rationale for cancer use (enhancing immune surveillance) is biologically sound, but clinical evidence has not matured beyond preliminary observations

reviewed april 2026|next review october 2026|88 physicians psi has verified|856 published studies

Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced by the thymus gland, a small organ behind the breastbone that regulates T-cell development, and it is marketed as Zadaxin in over 35 countries. It is not FDA-approved in the United States.

Evidence landscape: 856 published studies

856 published items: 61 human studies and 105 animal studies. An internationally established evidence base supporting regulatory approval in more than 35 countries.

61 Human
105 Animal
34 Reviews
656 Other research

Approved as a prescription medication in over 35 countries under the brand name Zadaxin (thymalfasin) for chronic hepatitis B and as an immune adjuvant. Not FDA-approved in the United States, meaning a U.S. doctor cannot write a standard prescription for it.

Substantial human clinical trial data across chronic hepatitis B, cancer immunotherapy adjunct, sepsis, and vaccine enhancement. Most pivotal trials were conducted outside the United States, which is part of why the FDA approval process was never completed.

U.S. access through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient, has shifted multiple times since 2023 and is currently uncertain. The final status is expected to be resolved after FDA review.

PSI Assessment

Approved as a prescription medication in more than 35 countries and used clinically for decades, thymosin alpha-1 occupies one of the most unusual positions in the peptide space: internationally established, but never FDA-approved in the United States. The clinical evidence supporting those approvals includes multiple controlled trials in chronic hepatitis B and more than 50 human studies across immune-modulation indications. The U.S. regulatory gap reflects an incomplete FDA approval process, not a documented safety or efficacy failure.

Approved in 35+ countries. Not approved in the U.S. Both are true simultaneously, and the gap is an incomplete U.S. approval process, not a clinical failure.

The mechanism is immune modulation rather than immune stimulation. Thymosin alpha-1 promotes T-cell maturation, enhances dendritic cell activation, and helps the immune system balance its response rather than simply amplify it. This restorative profile explains why it shows benefit in immunocompromised populations (chronic hepatitis, cancer, elderly vaccine recipients) but has less clear effect in healthy adults with normal immune function.

What the evidence supports

Approved in more than 35 countries with decades of clinical use. Multiple controlled trials support the chronic hepatitis B indication. The safety record across international use is strong.

What is not yet established

FDA approval in the United States. Whether the cancer immunotherapy adjunct evidence will hold up in large checkpoint-inhibitor-era trials. Whether healthy adults with normal immune function derive meaningful benefit.

Research Evidence

The findings below cover what international clinical use has established and where the evidence has limits.

Evidence by condition

Evidence dimensions across thymosin alpha-1's clinical indications. Chronic hepatitis B and vaccine enhancement have the deepest evidence with replication. Cancer adjunct and sepsis have human data but limited replication.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Hepatitis B (chronic)
Cancer Immunotherapy Adjunct
Immune Modulation
Sepsis
Vaccine Enhancement

Zadaxin (the brand name for thymosin alpha-1) first launched in Italy in 1996. Subsequent approvals span Asia, Latin America, and parts of Europe and the Middle East. China is the largest clinical use base.

The international approval footprint is unusual for a peptide never submitted for FDA approval. The Italy-first pathway came years before the international expansion that followed.

The strongest clinical evidence is in chronic hepatitis B, where controlled trials show improved viral clearance when Thymosin Alpha-1 is added to interferon therapy.

This is the indication that drove international approval. The evidence comes primarily from Asian clinical trials. Combination therapy design makes the independent contribution of Thymosin Alpha-1 difficult to isolate, which was part of the FDA pathway challenge.

Cancer immunotherapy adjunct evidence is developing, with studies in melanoma, hepatocellular carcinoma, and non-small cell lung cancer. No large checkpoint-inhibitor-era oncology RCT has been completed.

The rationale (enhancing immune surveillance alongside chemotherapy or checkpoint inhibitors) is biologically sound. But the clinical evidence is mostly small studies, case series, and pre-checkpoint-era combinations.

61 Human|105 Animal|34 Reviews

View all 856 indexed studies

How Thymosin Alpha-1 Works

Thymosin Alpha-1 is a 28-amino-acid peptide, which means it is a short chain of building blocks that normally make up proteins. It is naturally produced by the thymus gland, a small organ in your chest that trains the immune system's T-cells.

Your thymus gland trains the T-cells that coordinate your immune response, and Thymosin Alpha-1 is the signal it uses to do that. By supplementing this signal, researchers have found it can strengthen immune responses in people with weakened immunity or chronic infections.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Thymosin Alpha-1 binds to Toll-like receptors (TLR2 and TLR9) on dendritic cells, which are the immune system's sentinel cells that present antigens to T-cells. This activates pathways that upregulate antigen presentation and push the immune balance toward cell-mediated (Th1) immunity over antibody-dominated (Th2) responses. It also activates natural killer cells and increases interferon production. Unlike a broad immune stimulant, it appears to restore rather than overstimulate immune function, which is why it is studied as an adjunctive therapy alongside antivirals, vaccines, and cancer treatments rather than as a standalone agent.

What is Thymosin Alpha-1 being studied for?

Researchers are studying Thymosin Alpha-1 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymosin Alpha-1 overall. This means a compound can have human studies for one condition but only animal data for another.

Hepatitis B (chronic)

·Human Trials

Controlled trials demonstrate improved viral clearance when Thymosin Alpha-1 is combined with interferon therapy. This is the most evidence-supported indication and the basis for international regulatory approval in 35+ countries.

Limitations: Most pivotal trials were conducted in Asia. Combination therapy design makes it difficult to isolate the independent effect. The FDA did not approve based on available trial data.

Cancer Immunotherapy Adjunct

·Human Trials

Studies across melanoma, hepatocellular carcinoma, and non-small cell lung cancer show improved response rates when Thymosin Alpha-1 is added to chemotherapy or checkpoint inhibitors.

Limitations: No large randomized oncology trials in the checkpoint-inhibitor era have been completed. Effects as a standalone anti-cancer agent are not established.

Immune Modulation

·Human Trials

Clinical trials demonstrate enhanced T-cell maturation, dendritic cell function, and NK cell activity. The immune modulation effect is consistent across indications.

Limitations: Most evidence is in immunocompromised populations. Whether it provides meaningful benefit to healthy, immunocompetent adults is not established.

Sepsis

·Animal Studies

Earlier trials in septic patients showed improved survival in some subgroups, particularly those with low T-cell counts. A 2025 multicenter RCT added nuance.

Limitations: Trial results across the sepsis literature are mixed. Patient selection (which subgroups benefit) is poorly defined. This remains an area of active investigation without consensus.

Vaccine Enhancement

·Animal Studies

Clinical data shows improved antibody responses to influenza and hepatitis B vaccines in elderly and immunocompromised populations that typically respond poorly to vaccination alone.

Limitations: Most vaccine adjuvant studies are small. The clinical significance of improved antibody titers compared with actual infection prevention is not always established.

Safety and Regulatory Status

FDA Status: Not approved in the United States for any indication. The specific U.S. trial package the FDA requires was never completed, despite approvals elsewhere.

International status: Approved in more than 35 countries as Zadaxin (thymalfasin) for chronic hepatitis B and as an immune adjuvant. The European Medicines Agency declined approval in 2006 on trial-design grounds.

U.S. access: U.S. access through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient, has shifted multiple times since 2023 and is currently uncertain. The final status is expected to be resolved after FDA review.

Thymosin Alpha-1 has been administered to thousands of patients across decades of international clinical use with a notably favorable safety profile. The most commonly reported side effects are mild injection-site reactions. Serious adverse events are rare.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a Thymosin Alpha-1 discussion.

Comparison and Related Research

Thymosin Alpha-1 is most often compared with other immune-modulating peptides. The comparisons below break down how each differs in mechanism, evidence base, and regulatory status.

Head-to-head comparisons

Full research comparisons covering Thymosin Alpha-1 and another peptide side by side.

Thymosin Alpha-1 vs BPC-157

Research comparison of Thymosin Alpha-1 and BPC-157, an immune-modulating thymic peptide versus a tissue repair gastric peptide. Mechanisms, evidence levels, and use cases analyzed.

View full comparison

Thymosin Alpha-1 vs LL-37

Thymosin Alpha-1 has clinical approval in some countries. LL-37 is primarily preclinical. Evidence-graded comparison of two immune modulation peptides.

View full comparison

Thymosin Alpha-1 vs Thymosin Beta-4

Same organ of origin, completely different functions. TA1 modulates immune response. TB4 promotes tissue repair. Evidence-graded comparison.

View full comparison

Related compounds

LL-37 Selank Thymosin Beta-4 KPV

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Comprehensive review of the biology of thymosin alpha-1 and the clinical evidence base supporting its use as an immune modulator in hepatitis and other indications.Tuthill C, Rios I, 2010 in Ann N Y Acad Sci. View on PubMed
2.Review of preclinical and clinical research on thymosin alpha-1 in oncology, summarizing decades of evidence for its role as an immune adjuvant.Garaci E et al., 2012 in Int Immunopharmacol. View on PubMed
3.Randomized study in metastatic melanoma comparing thymosin alpha-1, interferon alfa, and their combination alongside chemotherapy. One of the larger oncology trials of the peptide.Maio M et al., 2007 in Ann Oncol. View on PubMed
4.Controlled trial showing improved viral clearance when thymosin alpha-1 was combined with interferon alpha-2b for chronic hepatitis B, a key study supporting international approval.Saruç M et al., 2003 in World J Gastroenterol. View on PubMed
5.Meta-analysis of randomized trials of thymosin alpha-1 combined with interferon in chronic hepatitis B, supporting improved virological response compared with interferon alone.You J et al., 2005 in World J Gastroenterol. View on PubMed
6.Systematic review summarizing clinical outcomes when thymosin alpha-1 is added to conventional cancer therapy across multiple tumor types.Wu J et al., 2018 in JAMA Netw Open. View on PubMed
7.Multicentre double-blind placebo-controlled trial of thymosin alpha-1 in sepsis. Results add nuance to earlier mixed sepsis evidence and inform subgroup analyses.Liu D et al., 2025 in BMJ. View on PubMed
8.Observational study reporting reduced mortality in severe COVID-19 patients receiving thymosin alpha-1, attributed to immune restoration. Observational, not randomized.Liu Y et al., 2020 in Clin Infect Dis. View on PubMed
9.Clinical study evaluating thymosin alpha-1 as an immune modulator in severe acute pancreatitis, reporting reduced inflammation and infection rates.Chen et al., 2025 in Clinical publication. View on PubMed
10.Mechanism study showing how thymosin alpha-1 activates specific dendritic cell pathways to balance inflammatory and regulatory immune responses.Romani L et al., 2012 in Int Immunopharmacol. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.